Brokerages Set Senseonics Holdings, Inc. (NYSE:SENS) Price Target at $22.70

Senseonics Holdings, Inc. (NYSE:SENS) has earned a consensus recommendation of “Buy” from the six brokerages that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and two have given a strong buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $22.70.

A number of research analysts have issued reports on the stock. TD Cowen decreased their target price on shares of Senseonics from $25.00 to $15.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. HC Wainwright increased their price objective on Senseonics to $18.50 and gave the company a “buy” rating in a report on Thursday, November 6th. Barclays reiterated an “overweight” rating and set a $31.00 target price (up previously from $1.50) on shares of Senseonics in a research report on Wednesday, November 5th. Finally, Stifel Nicolaus assumed coverage on Senseonics in a research report on Tuesday, October 21st. They set a “hold” rating and a $9.00 target price on the stock.

Insider Buying and Selling

In related news, CFO Frederick T. Sullivan purchased 5,415 shares of the business’s stock in a transaction on Friday, November 7th. The stock was acquired at an average price of $5.88 per share, with a total value of $31,840.20. Following the purchase, the chief financial officer directly owned 157,028 shares in the company, valued at approximately $923,324.64. This represents a 3.57% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Edelman Steven purchased 10,000 shares of the firm’s stock in a transaction on Monday, November 10th. The stock was bought at an average cost of $6.55 per share, for a total transaction of $65,500.00. Following the completion of the purchase, the director directly owned 74,708 shares in the company, valued at approximately $489,337.40. This trade represents a 15.45% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have acquired 30,415 shares of company stock worth $184,790. Corporate insiders own 3.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. CTC Alternative Strategies Ltd. purchased a new position in Senseonics during the 1st quarter valued at approximately $31,000. State of Wyoming acquired a new stake in Senseonics during the 1st quarter valued at approximately $40,000. Smith Salley Wealth Management boosted its position in Senseonics by 10.9% in the 3rd quarter. Smith Salley Wealth Management now owns 61,000 shares of the company’s stock worth $27,000 after purchasing an additional 6,000 shares in the last quarter. Elite Life Management LLC acquired a new stake in Senseonics in the second quarter valued at approximately $36,000. Finally, HBK Sorce Advisory LLC acquired a new stake in Senseonics in the 3rd quarter worth about $39,000. 12.36% of the stock is currently owned by institutional investors.

Senseonics Stock Up 5.1%

Shares of Senseonics stock opened at $7.02 on Friday. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47. The business’s 50 day simple moving average is $7.15 and its 200 day simple moving average is $8.89. The firm has a market cap of $286.83 million, a PE ratio of -54.00 and a beta of 0.92. Senseonics has a 52-week low of $5.25 and a 52-week high of $28.00.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.